[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer

Isabella Raccagni, Sara Belloli, Silvia Valtorta, A Stefano, L Presotto, C Pascali, A Bogni, M Tortoreto, N Zaffaroni, MG Daidone, G Russo, Emilio Bombardieri, Rosa Maria Moresco

Research output: Contribution to journalArticle

Abstract

Rationale Pathological response to neo-adjuvant chemotherapy (NAC) represents a commonly used predictor of survival in triple negative breast cancer (TNBC) and the need to identify markers that predict response to NAC is constantly increasing. Aim of this study was to evaluate the potential usefulness of PET imaging with [18F]FDG and [18F]FLT for the discrimination of TNBC responders to Paclitaxel (PTX) therapy compared to the response assessed by an adapted Response Evaluation Criteria In Solid Tumors (RECIST) criteria based on tumor volume (Tumor Volume Response). Methods Nu/nu mice bearing TNBC lesions of different size were evaluated with [18F]FDG and [18F] FLT PET before and after PTX treatment. SUVmax, Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) and Proliferation (TLP) were assessed using a graph-based random walk algorithm. Results We found that in our TNBC model the variation of [18F]FDG and [18F]FLT SUVmaxsimilarly defined tumor response to therapy and that SUVmaxvariation represented the most accurate parameter. Response evaluation using Tumor Volume Response (TVR) showed that the effectiveness of NAC with PTX was completely independent from lesions size at baseline. Conclusions Our study provided interesting results in terms of sensitivity and specificity of PET in TNBC, revealing the similar performances of [18F]FDG and [18F]FLT in the identification of responders to Paclitaxel. © 2018 Raccagni et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Original languageEnglish
Article numbere0197754
JournalPLoS One
Volume13
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint

Triple Negative Breast Neoplasms
Chemotherapy
Fluorodeoxyglucose F18
Adjuvant Chemotherapy
breast neoplasms
drug therapy
adjuvants
Tumors
Paclitaxel
Tumor Burden
paclitaxel
neoplasms
Bearings (structural)
positron-emission tomography
Glycolysis
Licensure
therapeutics
glycolysis
Reproduction
Therapeutics

Cite this

[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. / Raccagni, Isabella; Belloli, Sara; Valtorta, Silvia; Stefano, A; Presotto, L; Pascali, C; Bogni, A; Tortoreto, M; Zaffaroni, N; Daidone, MG; Russo, G; Bombardieri, Emilio; Moresco, Rosa Maria.

In: PLoS One, Vol. 13, No. 5, e0197754, 2018.

Research output: Contribution to journalArticle

Raccagni, I, Belloli, S, Valtorta, S, Stefano, A, Presotto, L, Pascali, C, Bogni, A, Tortoreto, M, Zaffaroni, N, Daidone, MG, Russo, G, Bombardieri, E & Moresco, RM 2018, '[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer', PLoS One, vol. 13, no. 5, e0197754. https://doi.org/10.1371/journal.pone.0197754
Raccagni, Isabella ; Belloli, Sara ; Valtorta, Silvia ; Stefano, A ; Presotto, L ; Pascali, C ; Bogni, A ; Tortoreto, M ; Zaffaroni, N ; Daidone, MG ; Russo, G ; Bombardieri, Emilio ; Moresco, Rosa Maria. / [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. In: PLoS One. 2018 ; Vol. 13, No. 5.
@article{9c6dc4a04b1646818033efd514f56508,
title = "[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer",
abstract = "Rationale Pathological response to neo-adjuvant chemotherapy (NAC) represents a commonly used predictor of survival in triple negative breast cancer (TNBC) and the need to identify markers that predict response to NAC is constantly increasing. Aim of this study was to evaluate the potential usefulness of PET imaging with [18F]FDG and [18F]FLT for the discrimination of TNBC responders to Paclitaxel (PTX) therapy compared to the response assessed by an adapted Response Evaluation Criteria In Solid Tumors (RECIST) criteria based on tumor volume (Tumor Volume Response). Methods Nu/nu mice bearing TNBC lesions of different size were evaluated with [18F]FDG and [18F] FLT PET before and after PTX treatment. SUVmax, Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) and Proliferation (TLP) were assessed using a graph-based random walk algorithm. Results We found that in our TNBC model the variation of [18F]FDG and [18F]FLT SUVmaxsimilarly defined tumor response to therapy and that SUVmaxvariation represented the most accurate parameter. Response evaluation using Tumor Volume Response (TVR) showed that the effectiveness of NAC with PTX was completely independent from lesions size at baseline. Conclusions Our study provided interesting results in terms of sensitivity and specificity of PET in TNBC, revealing the similar performances of [18F]FDG and [18F]FLT in the identification of responders to Paclitaxel. {\circledC} 2018 Raccagni et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",
author = "Isabella Raccagni and Sara Belloli and Silvia Valtorta and A Stefano and L Presotto and C Pascali and A Bogni and M Tortoreto and N Zaffaroni and MG Daidone and G Russo and Emilio Bombardieri and Moresco, {Rosa Maria}",
year = "2018",
doi = "10.1371/journal.pone.0197754",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer

AU - Raccagni, Isabella

AU - Belloli, Sara

AU - Valtorta, Silvia

AU - Stefano, A

AU - Presotto, L

AU - Pascali, C

AU - Bogni, A

AU - Tortoreto, M

AU - Zaffaroni, N

AU - Daidone, MG

AU - Russo, G

AU - Bombardieri, Emilio

AU - Moresco, Rosa Maria

PY - 2018

Y1 - 2018

N2 - Rationale Pathological response to neo-adjuvant chemotherapy (NAC) represents a commonly used predictor of survival in triple negative breast cancer (TNBC) and the need to identify markers that predict response to NAC is constantly increasing. Aim of this study was to evaluate the potential usefulness of PET imaging with [18F]FDG and [18F]FLT for the discrimination of TNBC responders to Paclitaxel (PTX) therapy compared to the response assessed by an adapted Response Evaluation Criteria In Solid Tumors (RECIST) criteria based on tumor volume (Tumor Volume Response). Methods Nu/nu mice bearing TNBC lesions of different size were evaluated with [18F]FDG and [18F] FLT PET before and after PTX treatment. SUVmax, Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) and Proliferation (TLP) were assessed using a graph-based random walk algorithm. Results We found that in our TNBC model the variation of [18F]FDG and [18F]FLT SUVmaxsimilarly defined tumor response to therapy and that SUVmaxvariation represented the most accurate parameter. Response evaluation using Tumor Volume Response (TVR) showed that the effectiveness of NAC with PTX was completely independent from lesions size at baseline. Conclusions Our study provided interesting results in terms of sensitivity and specificity of PET in TNBC, revealing the similar performances of [18F]FDG and [18F]FLT in the identification of responders to Paclitaxel. © 2018 Raccagni et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

AB - Rationale Pathological response to neo-adjuvant chemotherapy (NAC) represents a commonly used predictor of survival in triple negative breast cancer (TNBC) and the need to identify markers that predict response to NAC is constantly increasing. Aim of this study was to evaluate the potential usefulness of PET imaging with [18F]FDG and [18F]FLT for the discrimination of TNBC responders to Paclitaxel (PTX) therapy compared to the response assessed by an adapted Response Evaluation Criteria In Solid Tumors (RECIST) criteria based on tumor volume (Tumor Volume Response). Methods Nu/nu mice bearing TNBC lesions of different size were evaluated with [18F]FDG and [18F] FLT PET before and after PTX treatment. SUVmax, Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) and Proliferation (TLP) were assessed using a graph-based random walk algorithm. Results We found that in our TNBC model the variation of [18F]FDG and [18F]FLT SUVmaxsimilarly defined tumor response to therapy and that SUVmaxvariation represented the most accurate parameter. Response evaluation using Tumor Volume Response (TVR) showed that the effectiveness of NAC with PTX was completely independent from lesions size at baseline. Conclusions Our study provided interesting results in terms of sensitivity and specificity of PET in TNBC, revealing the similar performances of [18F]FDG and [18F]FLT in the identification of responders to Paclitaxel. © 2018 Raccagni et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

U2 - 10.1371/journal.pone.0197754

DO - 10.1371/journal.pone.0197754

M3 - Article

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0197754

ER -